Latest Breaking News On - Fruquintinib approval - Page 4 : comparemela.com

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet - HUTCHMED (China) (NASDAQ:HCM), Takeda Pharmaceutical (NYSE:TAK)

Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) Data support regulatory submissions in the U.S.,

Hong kongUnited kingdomUnited statesAl qahirahSara noonanJemma nashAhcene djaballahJun saitoEli lillyGastroenterol hepatolEuropean medicines agencyJapan pharmaceuticalsEuropean society for medical oncology congressTakeda pharmaceutical company limitedExchange commissionChina national reimbursement drug list

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO2 Results in The Lancet

Takeda TSE4502NYSETAK and HUTCHMED China Limited NasdaqAIMHCM HKEX13 HUTCHMED today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer CRC were published in The Lancet.

United statesHong kongAl qahirahEli lillyBen atwell alex shawAnnie chengGastroenterol hepatolMark leeAhcene djaballahJemma nashJun saitoSara noonanZhou yiEuropean society for medical oncology congressJapan pharmaceuticalsSolebury strategic communications

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet

OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J. (BUSINESS WIRE) Jun 15, 2023

Al qahirahUnited statesHong kongBen atwell alex shawJemma nashGastroenterol hepatolSara noonanMark leeZhou yiJun saitoAnnie chengEli lillyAhcene djaballahDrug administrationJapan pharmaceuticalsTakeda pharmaceutical company limited

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomAl qahirahGastroenterol hepatolJun saitoBen atwell alex shawPanmure gordonEli lillyMark leeZhou yiJemma nashSara noonanAhcene djaballahAnnie chengTakeda pharmaceutical company limited

HUTCHMED Completes Rolling Submission of NDA to U S FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

HUTCHMED Completes Rolling Submission of NDA to U S FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongMichael shiMark leeZhou yiBen atwell alex shawAtholl tweedie freddy crossleyAnnie chengEli lillyNational cancer instituteChina national medical products administrationDrug administrationTakeda pharmaceutical company limitedJapan pharmaceuticalsJournal of the american medical associationChina limited